# Development and validation of a risk prediction tool for the diagnosis of inflammatory bowel disease in patients presenting in primary care with abdominal symptoms

## TL;DR

This study created a tool to help doctors in primary care identify patients who might have inflammatory bowel disease based on symptoms and other factors.

## Contribution

The novel contribution is a validated risk prediction model for IBD, UC, and CD using primary care data.

## Key findings

- The model showed good discrimination with a C-statistic of 0.78 for both men and women.
- The model slightly overestimated IBD risk in the validation cohort at higher thresholds.
- Key predictors included age, smoking, BMI, symptoms, and lab results.

## Abstract

Patients with inflammatory bowel disease (IBD) may experience delays in their diagnosis. This study aimed to develop and validate a risk prediction tool for IBD.

A retrospective cohort study was conducted using primary care data from 2010 to 2019, including symptomatic patients aged ≥18. UK-based primary care databases linked to hospital records were utilized for model development and validation. Cox proportional hazards models were used to derive risk equations for IBD, ulcerative colitis (UC), and Crohn’s disease (CD) in men and women. Candidate predictors included demographics, comorbidities, symptoms, extraintestinal manifestations, and laboratory results. Model performance was evaluated using measures of fit, discrimination, and calibration at 1, 2, 3, and 5 years after symptom onset.

In total, 2 054 530 patients were included in the derivation cohort and 673 320 in the validation cohort. In the derivation cohort, 0.7% were diagnosed with IBD (66.3% UC and 33.7% CD). Predictors in the final IBD model included age, smoking, body mass index, gastrointestinal symptoms, extraintestinal manifestations, comorbidities, family history of IBD, and laboratory investigations. The model demonstrated good discrimination and calibration; C-statistic 0.78 (95% confidence interval [CI], 0.77–0.79) in men and 0.78 (95% CI, 0.77–0.79) in women. In the validation cohort, the model tended to slightly overestimate IBD risk at higher risk thresholds.

A risk model using patient demographics, symptoms, and laboratory results accurately predicted IBD, UC, and CD at 1, 2, 3, and 5 years after symptom onset, potentially aiding in prioritizing patients for a referral or fecal calprotectin testing in primary care.

Graphical Abstract